We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look ...

Evercore ISI notes that Vaxcyte (PCVX) missed four serotypes versus Prevnar20 in the “all-important” infant data, adding that ...

Vaxcyte, Inc.'s positive phase 2 results for VAX-24 show promise in preventing invasive pneumococcal disease in infants.

Vaxcyte (NASDAQ:PCVX – Free Report) had its price target cut by The Goldman Sachs Group from $138.00 to $100.00 in a report ...

BofA lowered the firm’s price target on Vaxcyte (PCVX) to $137 from $157 following the company’s report of Phase 2 dose-finding data for VAX-24 ...

Vaxcyte’s stock price dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an ...

Needham lowered the firm’s price target on Vaxcyte (PCVX) to $90 from $140 and keeps a Buy rating on the shares after the company announced ...

(Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the ...

Vaxcyte (NASDAQ:PCVX – Get Free Report) had its target price lowered by investment analysts at Needham & Company LLC from ...

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...

Stock futures edged lower on Monday due to trade war concerns and the upcoming 25% levy on non-US cars. President Trump has ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Vaxcyte Inc (Symbol: PCVX), where a total volume of 7,810 contracts has been ...